Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion

Patients with metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) are widely treated with osimertinib, the preferred first-line treatment option. However, disease progression inevitably occurs, driven by EGFR-dependent or EGFR-independent mechanisms of resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Sandip, Patel, Jyoti D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611612/
https://www.ncbi.nlm.nih.gov/pubmed/37801233
http://dx.doi.org/10.1007/s12325-023-02680-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611612/
https://www.ncbi.nlm.nih.gov/pubmed/37801233
http://dx.doi.org/10.1007/s12325-023-02680-1

Ejemplares similares